Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease

Neurology

Volumn 61, Issue 11 SUPPL. 6, 2003, Pages

  Schwarzschild, Michael A ^a   Xu, Kui ^a   Oztas, Emin ^c   Petzer, Jacobus P ^b   Castagnoli, Kay ^b   Castagnoli Jr , Neal ^b   Chen, Jiang Fan ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; CAFFEINE;

DISEASE COURSE; DOPAMINERGIC NERVE CELL; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STRIATONIGRAL DEGENERATION;

EID: 0344306440     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000095214.53646.72     Document Type: Review

References (70)

1. Ascherio A, Chen H. Caffeinated clues in Parkinson's disease. Neurology 2003;61(suppl 6):S51-S54.
2. 2A adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001;21:RC143.
3. Xu K, Xu Y-H, Chen J-F, Schwarzschild MA. Caffeine's neuroprotection against MPTP toxicity shows no tolerance to chronic caffeine administration. Neurosci Lett 2002;322:13-16.
4. Oztas E, Kalda A, Xu K, Irrizary MC, Schwarzschild MA, Chen J. Caffeine attenuates MPTP-induced loss of dopaminergic neurons in substantia nigra in mice. Soc Neurosci 2002;A487.6. Abstract.
5. Xu K, Xu Y-H, Chen J-F, Schwarzschild MA. Neuroprotection by metabolites of caffeine may prolong its neuroprotective effect in the MPTP model of PD. Soc Neurosci 2002;A487.5. Abstract.
6. Gerlach M, Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 1996;103:987-1041.
7. Benowitz NL, Jacob P III, Mayan H, Denaro C. Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther 1995;58:684-691.
8. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83-133.
9. Morgan KJ, Stults VJ, Zabik ME. Amount and dietary sources of caffeine and saccharin intake by individuals ages 5 to 18 years. Regul Toxicol Pharmacol 1982;2:296-307.
10. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Cotreau MM, Harmatz JS, Shader RI. Pharmacokinetics and psychomotor effects of caffeine. J Clin Pharmacol 1997;37:693-703.
11. Holtzman SG, Mante S, Minneman KP. Role of adenosine receptors in caffeine tolerance. J Pharmacol Exp Ther 1991;256:62-68.
12. Kaplan GB, Greenblatt DJ, Kent MA, Cotreau-Bibbo MM. Caffeine treatment and withdrawal in mice: relationships between dosage, concentrations, locomotor activity and A1 adenosine receptor binding. J Pharmacol Exp Ther 1993;266:1563-1572.
13. 2A receptors. Prog Neurobiol 1999;59:355-396.
14. 2A receptor antagonism. J Biol Chem 2002;277:36040-36044.
15. 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 2002;80:262-270.
16. 2A receptor antagonists. Bioorg Med Chem 2003;11:1299-1310.
17. 2AR. Nature 1997;388:674-678.
18. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal Ischemia in mice. J Neurosci 1999;19:9192-9200.
19. 2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 2002;22:1967-1975.
20. 2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J Neurochem 2003 (in press).
21. A receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000;97:505-519.
22. 2A receptor antagonist. Brain Res 1998;800:328-335.
23. 2A receptor antagonists. Drug Dev Res 2001;52:323-330.
24. Gao Y, Phillis JW. CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischaemic injury in the Mongolian gerbil. Life Sci 1994;55:PL61-PL65.
25. 2a adenosine receptor antagonists on cerebral ischaemic injury in the gerbil. Brain Res 1995;705:79-84.
26. 2A receptor agonists and antagonists. Eur J Pharmacol 1995;287:295-302.
27. 2A adenosine receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 1998;9:3955-3959.
28. Strong R, Grotta JC, Aronowski J. Combination of low dose ethanol and caffeine protects brain from damage produced by focal ischemia in rats. Neuropharmacology 2000;39:515-522.
29. Aronowski J, Strong R, Shirzadi A, Grotta JC. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke 2003;34:1246-1251.
30. Piriyawat P, Labiche LA, Burgin WS, Aronowski JA, Grotta JC. Pilot dose-escalation study of caffeine plus ethanol (caffeinol) in acute ischemic stroke. Stroke 2003;34:1242-1245.
31. 2A receptor blockade of β-amyloid neurotoxicity. Br J Pharmacol 2003;138:1207-1209.
32. Ohta A, Sitovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001;414:916-920.
33. 2A adenosine receptor: a novel therapeutic target in renal disease. Am J Physiol Renal Physiol 2002;282:F10-F18.
34. Lozza G, Conti A, Ongini E, Monopoli A. Cardioprotective effects of adenosine A1 and A2A receptor agonists in the isolated rat heart. Pharmacol Res 1997;35:57-64.
35. Belardinelli L, Shryock JC, Snowdy S, et al. The A2A adenosine receptor mediates coronary vasodilation. J Pharmacol Exp Ther 1998;284:1066-1073.
36. 2A adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am J Physiol Renal Physiol 2000;279:F809-F818.
37. 2A agonist, ATL-146e, reduces paralysis, and apoptosis during rabbit spinal cord reperfusion. J Vasc Surg 2001;34:482-488.
38. 3H]CGS 21680. Eur J Pharmacol 1989;168:243-246.
39. Schiffmann SN, Jacobs O, Vanderhaeghen JJ. The striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons. An in situ hybridisation histochemistry study. J Neurochem 1991;57:1062-1067.
40. Fink JS, Weaver DR, Rivkees SA, et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Mol Brain Res 1992;14:186-190.
41. Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 1996;118:1461-1468.
42. Hettinger BD, Lee A, Linden J, Rosin DL. Adenosine A2A receptors in rat striatum: prevalent dendritic localization post-synaptic to catecholaminergic terminals. Soc Neurosci 1998;24:2056.
43. Appel SH. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer's disease. Ann Neurol 1981;10:499-505.
44. Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Rev 2000;33:199-227.
45. Mayfield RD, Larson G, Orona RA, Zahniser NR. Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2a/D2 receptor interaction in globus pallidus. Synapse 1996;22:132-138.
46. Shindou T, Mori A, Kase H, Ichimura M. Adenosine A(2A) receptor enhances GABA(A)-mediated IPSCs in the rat globus pallidus. J Physiol 2001;532:423-434.
47. Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 2000;62:63-88.
48. Greenamyre JT. Glutamatergic influences on the basal ganglia. Clin Neuropharmacol 2001;24:65-70.
49. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992;42:733-738.
50. Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996;8:1408-1414.
51. Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML, During MJ. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002;298:425-429.
52. Sebastiao AM, Ribeiro JA. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol 1996;48:167-189.
53. 2A agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex. Neurosci Lett 1992;138:169-172.
54. Castillo-Melendez M, Krstew E, Lawrence AJ, Jarrott B. Presynaptic adenosine A2a receptors on soma and central terminals of rat vagal afferent neurons. Brain Res 1994;652:137-144.
55. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats Eur J Pharmacol 1995;287:215-217.
56. 2A receptor activation on the evoked release of glutamate from rat cerebro cortical synaptosomes. Br J Pharmacol 2002;136:434-440.
57. 2A receptors suggests multiple cellular sites for modula tion of GABAergic neurons in rat striatum. J Comp Neurol 2001;431:331-346.
58. Corsi C, Melani M, Bianchi L, Pedata F. Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport 2000;11:1-5.
59. Pintor A, Quarta D, Pezzola A, Reggio R, Popoli P. SCH 58261 (an adenosine A(2A) receptor antagonist) reduces, only at low doses, K(+)-evoked glutamate release in the striatum. Eur J Pharmacol 2001;421:177-180.
60. 2A receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices. Neuropharmacology 2003;45:201-210.
61. Melani A, Pantoni L, Bordoni F, et al. The selective A(2A) receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res 2003;959:243-250.
62. Li XX, Nomura T, Aihara H, Nishizaki T. Adenosine enhances glial glutamate efflux via A2a adenosine receptors. Life Sci 2001;68:1343-1350.
63. Nishizaki T, Nagai K, Nomura T, et al. A new neuromodulatory pathway with a glial contribution mediated via A(2a) adenosine receptors. Glia 2002;39:133-147.
64. Fiebich BL, Biber K, Lieb K, et al. Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 1996;18:152-160.
65. 2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett 1998;429:139-142.
66. Merighi S, Mirandola P, Milani D, et al. Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol 2002;119:923-933.
67. 2A receptor inactivation in an MPTP model of Parkinson's disease. Mov Disord 2000;15(suppl 3):37. Abstract P304.
68. 2A antagonists in Parkinson's disease. Neurology 2002;58:1154-1160.
69. 2A receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-296.
70. 2A receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303.